RSS-Feed abonnieren
DOI: 10.1055/s-0031-1280666
Hepatic Transcatheter Arterial Chemoembolization Complicated by Postembolization Syndrome
Publikationsverlauf
Publikationsdatum:
16. Juni 2011 (online)
![](https://www.thieme-connect.de/media/sir/201102/lookinside/thumbnails/10.1055-s-0031-1280666-1.jpg)
ABSTRACT
Postembolization syndrome (PES) is a common complication after embolic procedures, and it is a frequent cause of extended inpatient hospital admissions. PES is a self-limited constellation of symptoms consisting of fevers, unremitting nausea, general malaise, loss of appetite, and variable abdominal pain following the procedure. Although a definite cause is unknown, this syndrome is thought to be a result of therapeutic cytotoxicity, tumor ischemia, and resulting intrahepatic and extrahepatic inflammation. The authors report a case of PES precipitated by transcatheter intrarterial chemoembolization of hepatic metastases.
KEYWORDS
Postembolization syndrome (PES) - chemoembolization - hepatocellular carcinoma (HCC) - transcatheter arterial chemoembolization (TACE) - complications - embolization complications
REFERENCES
- 1 Paye F, Farges O, Dahmane M, Vilgrain V, Flejou J F, Belghiti J. Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg. 1999; 86 (2) 176-180
- 2 Leung D A, Goin J E, Sickles C, Raskay B J, Soulen M C. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001; 12 (3) 321-326
- 3 Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000; 62 (Suppl 1) 79-83
- 4 Lewandowski R J, Mulcahy M F, Kulik L M et al.. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology. 2010; 255 (3) 955-965
- 5 Sakamoto I, Aso N, Nagaoki K M et al.. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics. 1998; 18 (3) 605-619
- 6 Lewandowski R J, Sato K T, Atassi B et al.. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007; 30 (4) 571-592
- 7 Lee K H, Sung K B, Lee D Y, Park S J, Kim K W, Yu J S. Transcatheter arterial chemoembolization for hepatocellular carcinoma: anatomic and hemodynamic considerations in the hepatic artery and portal vein. Radiographics. 2002; 22 (5) 1077-1091
- 8 Chung J W, Park J H, Han J K et al.. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology. 1996; 198 (1) 33-40
- 9 Castells A, Bruix J, Ayuso C et al.. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol. 1995; 22 (4) 410-415
- 10 Romano M, Giojelli A, Tamburrini O, Salvatore M. Chemoembolization for hepatocellular carcinoma: effect of intraarterial lidocaine in peri- and post-procedural pain and hospitalization. Radiol Med (Torino). 2003; 105 (4) 350-355
- 11 Coldwell D M, Loper K A. Regional anesthesia for hepatic arterial embolization. Radiology. 1989; 172 (3 Pt 2) 1039-1040
- 12 Rinke A, Müller H H, Schade-Brittinger C PROMID Study Group et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27 (28) 4656-4663
Sabeen DhandM.D.
Department of Radiology, Northwestern University
676 North St. Clair Street, Chicago, IL 60611
eMail: sabeen.dhand@gmail.com